Fig. 2
PEPDG278D inhibits RAS and PI3K and targets EGFR mutants in CRC cells. a Western blotting of whole cell lysates from cells treated with solvent, PEPDG278D (25 nM), and cetuximab (275 nM) for 48 h. b, c Ras and PI3K activities in whole cell lysates from cells treated with solvent or PEPDG278D (25 nM) for 48 h. Each value is mean ± SD (n = 3). *P < 0.05, ****P < 0.0001 by two-tailed unpaired t test. d Western blotting of whole cell lysates from untreated cells or cells which were transfected with EGFR or its mutant and 24 h later treated with solvent or PEPDG278D (25 nM) for 48 h. p-MEK and p-EGFR/mutant are pS217/221-MEK and pY1173-EGFR, respectively